Corient Private Wealth
SPRO icon

Corient Private Wealth’s Spero Therapeutics SPRO Stock Holding History

Corient Private Wealth’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,500
Closed -$30.3K – 2050
2022
Q4 		$30.3K Buy
+17,500
New +$32.7K ﹤0.01% 1655

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corient Private Wealth's SPRO Position: Q1 2023 in Review

Corient Private Wealth sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 17,500 shares — an estimated $30.3K sold.

Corient Private Wealth first reported a position in SPRO in Q4 2022 and held it in 1 quarter. The position peaked at $30.3K in Q4 2022. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

  • Corient Private Wealth reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 17,500 Spero Therapeutics shares in Q1 2023, an estimated $30.3K.
  • Corient Private Wealth first reported a position in Spero Therapeutics in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's Spero Therapeutics position peaked at $30.3K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.